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CARDIOLOGY ®Original scientific paper
Time to improve statin prescription
guidelines in low-risk patients?
Jan W Balder1,2, Jeroen K de Vries2, Douwe J Mulder2
and Pieter W Kamphuisen2,3
Abstract
Background: The challenge of the primary prevention of cardiovascular disease (CVD) is to identify patients who
would benefit from treatment with statins. Statins are currently prescribed to many patients, even those at a low 10-year
risk of CVD. These latter patients may not be eligible for statins according to current guidelines.
Design: This study investigated the prescription of guideline-consistent (according to guidelines) and guideline-
inconsistent (not according to guidelines) lipid-lowering treatment in primary prevention in a large contemporary
Dutch cohort study (Lifelines).
Methods: Lifelines is a large cohort study from the Netherlands. Participants were recruited between 2006 and 2013.
They completed questionnaires and underwent a physical examination. Participants with previous CVD were excluded.
Statins and ezetimibe were grouped as statin treatment. The Dutch guideline on cardiovascular management was used to
assess eligibility for statins.
Results: Of 147,785 participants, 7092 (4.8%) reported statin treatment. In 4667 (66%) participants, statin treatment
was inconsistent with the Dutch guideline. A total of 78% of these participants had a low 10-year predicted CVD risk.
Multivariable logistic regression analysis showed that female sex and smoking were strongly associated with guideline-
inconsistent treatment. Interestingly, 65% of the these participants had low-density lipoprotein cholesterol levels above
the 95th percentile, adjusted for age and sex, two or more major risk factors of CVD or a positive family history of
premature CVD. Therefore treatment might be reasonable.
Conclusions: There is a large inconsistency between guideline recommendations and the prescription of statins in
clinical practice in the Netherlands. This is especially true for patients with low CVD risk. Many of these patients
probably had risk-increasing circumstances justifying treatment.
Keywords
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Introduction
Cardiovascular disease (CVD) is the leading cause of
death worldwide.1 Many prospective cohort studies
have shown that high levels of low-density lipoprotein
cholesterol (LDL-c) are a major risk factor for CVD.
HMG-CoA reductase inhibitors (statins) reduce all-
cause mortality and major vascular events by approxi-
mately 23% for each 1.0mmol/l lowering of LDL-c.2
The challenge of statin treatment is the identiﬁcation of
patients who would beneﬁt from treatment. Various
guidelines have been developed to guide physicians.3
The Dutch guideline is comparable with international
guidelines.4
Despite these guidelines, we have shown that 77% of
patients without CVD who met the criteria for statin
treatment in a large and representative cohort of the
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Dutch population did not receive lipid-lowering drugs.5
The prescription of statins to patients in the
Netherlands who are not eligible for statin treatment
according to guidelines may also be prevalent. Several
previous cohort studies have shown a high frequency of
guideline-inconsistent treatment, especially in low-risk
patients.6–9 However, these studies were most often
based on UK primary care records, involved relatively
small numbers of patients, or did not focus on primary
prevention.
The aim of this study was therefore to evaluate the
proportion of guideline-inconsistent (statin treatment
without guideline recommendation) and guideline-con-
sistent treatment (statin treatment with guideline rec-
ommendation) in a primary prevention setting and to
identify the factors associated with guideline-inconsis-
tent statin treatment in a large sample of the Dutch
population, the Lifelines cohort study.
Methods
Study design and participants
The Lifelines cohort study is a prospective population-
based study of the three northern provinces of the
Netherlands. Details of the design of the study have
been published elsewhere.10 Participants were included
in the study between 2006 and 2013. All general prac-
titioners from the three northern provinces of the
Netherlands were asked to invite patients aged between
25 and 50 years to participate in the Lifelines cohort
study. For those who agreed to participate, ﬁrst-degree
family members were also invited. Participants could
also register via the Lifelines website. In this analysis,
we focused on primary prevention and therefore par-
ticipants who reported myocardial infarction, stroke
or coronary revascularization procedures, deﬁned as
coronary angioplasty or bypass surgery, were excluded.
All participants provided written informed consent
and the study protocol was approved by the medical
ethical committee of the University Medical Center
Groningen, the Netherlands.
Questionnaires and physical examination
At baseline, all participants received a number of ques-
tionnaires concerning demographics, family structure,
medical history, lifestyle factors and use of medication.
Statins and ezetimibe were classiﬁed as statin treatment.
All participants visited the Lifelines research facility for
a basic medical examination including blood pressure
(ten times using a Dinamap automated blood pressure
monitor), body height and weight. In addition, urine
and blood samples were collected for storage and
laboratory measurements. The estimated glomerular
ﬁltration rate was estimated using the MDRD formula.
Total cholesterol, high-density lipoprotein cholesterol
(HDL-c) and LDL-c levels were measured directly
(Roche Modular P, Mannheim, Germany).
Triglycerides were measured using an enzymatic colori-
metric test (Roche Modular P).
Guideline-(in)consistent treatment
The indication to prescribe statins in the Netherlands is
based on the Cardiovascular Risk Management
(CVRM) guideline.4 In primary prevention, the pres-
ence of an extreme lipid proﬁle (TC/HDL-c >8) is an
indication for statin therapy. In all other cases, the
10-year predicted risk of morbidity or mortality of
CVD is estimated using prediction charts based on
the SCORE risk charts and national surveys. The esti-
mated 10-year predicted CVD risk is stratiﬁed as high
(20%), medium (10–19%) or low (<10%). The
cardiovascular risk of participants with rheumatoid
arthritis and diabetes mellitus is estimated by adding
15 years to their actual age. Those with a low 10-year
predicted CVD risk do not have an indication for statin
treatment. Subjects with a medium 10-year predicted
CVD risk with one or more additional risk factors
(sedentary lifestyle, positive family history of premature
CVD, obesity and renal failure) and LDL-
c> 2.5mmol/l are eligible for treatment. Participants
with a high 10-year predicted CVD risk and LDL-
c> 2.5mmol/l also have an indication for statin treat-
ment. Patients treated with statins who fulﬁlled one of
these criteria were classiﬁed as receiving guideline-con-
sistent treatment. The remaining statin-treated patients
were classiﬁed as receiving guideline-inconsistent
treatment.
Evaluation of guideline-inconsistent treatment
In patients with guideline-inconsistent statin prescrip-
tion, we analysed how many patients had an LDL-c
level above the 95th percentile, adjusted for age and
sex, had two or more major cardiovascular risk factors
(based on their lifetime risk of CVD11) or a positive
family history of premature CVD. In such patients,
statin treatment might be justiﬁed although the 10-
year predicted CVD risk is low.
Recalculation of LDL-c before statin treatment
The initiation of statin treatment is based on untreated
cholesterol levels. Statins reduce LDL-c levels by 10–
60% depending on the type and dose. If participants
reported statin treatment at baseline, the LDL-c levels
before statin treatment were unknown. Therefore cor-
rection factors were used to estimate the LDL-c and
Balder et al. 1065
total cholesterol levels before the initiation of statin
treatment.12 If the dose was not reported, the correction
factor of the lowest available dose was chosen to min-
imize the risk of classifying a statin prescription as
guideline-inconsistent.
Statistical analyses
PASW Statistics (version 23, IBM, Armonk, NY, USA)
was used for the statistical analysis. Normally distrib-
uted characteristics are presented as mean standard
deviation (SD) values. Categorical variables are pre-
sented as percentages. Student’s t-test was used to
assess the diﬀerence of normally distributed variables
between guideline-inconsistent and guideline-consistent
treated patients. In the case of categorical variables, the
Mann–Whitney U test was used. To identify risk factor
associated with guideline-inconsistent treatment, we
ﬁrst identiﬁed all statistically signiﬁcant subgroups in
univariate logistic regression (data not shown); these
risk factors were subsequently assessed in multivariate




Table 1 shows the baseline characteristics of the par-
ticipants included in our study. In total, 147,785 par-
ticipants were included in our analysis. The mean age
was 44 years (range 18–93 years). The mean SD total
cholesterol was 5.2 1.1mmol/l and the mean SD
LDL-c was 3.3 1.0mmol/l. The cohort consisted of
fewer men (n¼ 60,292 (41%)) than women. Based on
the Dutch cardiovascular risk prediction score, 92% of
the participants had a low 10-year predicted CVD risk,
4% had a medium risk and 4% had a high 10-year
predicted CVD risk.
Guideline-(in)consistent treatment
Table 2 shows the characteristics of the participants
with guideline-consistent and guideline-inconsistent
treatment. A total of 7092 (4.8%) participants reported
statin treatment; 4667 (66%) did not have a guideline-
based indication for statin prescription. Patients
with guideline-inconsistent treatment had lower base-
line total cholesterol levels (6.9 vs. 7.7mmol/l;
p< 0.001) and lower LDL-c levels (4.1 vs. 4.6mmol/l;
p< 0.001). Participants with guideline-consistent treat-
ment had signiﬁcantly higher systolic blood pressure
(139 vs. 130mmHg; p< 0.001). Women more often
had guideline-inconsistent treatment compared with
men (73 vs. 59%; p< 0.001). A total of 93% of the
3911 patients with a low 10-year predicted CVD risk
did not have a direct recommendation for statin treat-
ment. Of the statin-treated patients at medium 10-year
CVD risk, 64% were guideline-inconsistent. About
10% of the patients with a high 10-year CVD risk
were classiﬁed as guideline-inconsistent treatment
because their LDL-c was <2.5mmol/l before the initi-
ation of statin treatment.
Multivariate logistic regression analysis
In the multivariate analysis, the strongest predictors of
guideline-inconsistent treatment were female sex (odds
ratio (OR) 4.5; 95% conﬁdence interval (CI) 3.9–5.2),
current smoking (OR 4.2; 95% CI 3.6–5.1) and a posi-
tive family history of premature CVD (OR 2.4; 95%
CI 2.0–2.9) (Table 3). Patients with higher LDL-c (OR
0.47 per mmol/l increase; 95% CI 0.45–0.50) and
diabetes mellitus (OR 0.09; 95% CI 0.08–0.11) were
more likely to be classiﬁed as guideline-consistent
treatment.
Evaluation of guideline-inconsistent treatment
The presence of cardiovascular risk factors (based on
lifetime risks of CVD;11 see Supplementary Table 1,
available online) is shown for those with guideline-
inconsistent treatment (n¼ 4667; Table 4), separately
Table 1. Baseline characteristics of the Lifelines cohort.
Age (years) 44 13
Male sex 60,292 (41)
Systolic blood pressure (mmHg) 125 15
Diastolic blood pressure (mmHg) 74 11
Hypertension 22,120 (15)
Body mass index (kg/m2) 26 4.3
Current smoker 30,589 (21)
Diabetes mellitus 3319 (2.2)
Statin treatment 7092 (4.8)
Lipid levels (mmol/l)





Low (< 10%) 135,301 (92)
Medium (10–19%) 6573 (4)
High ( 20%) 5911 (4)
Data presented as mean SD values or n (%).
CVD: cardiovascular disease; HDL-c: high-density lipoprotein cholesterol;
LDL-c: low-density lipoprotein cholesterol.
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for men and women. When evaluating 4667 guideline-
inconsistent treated patients, 975 (21%) had LDL-c
levels above the 95th percentile adjusted for age and
sex, 2259 (48%) had two or more major risk factors
and 738 (16%) reported a positive family history of pre-
mature CVD. Because some patients had multiple risk
factors, a total of 1644 patients (35% of the total guide-
line-inconsistent treatment) had no discernible cause for
statin treatment (Figure 1).
Discussion
This study shows that, despite evidence-based recom-
mendations, 66% of the statin prescriptions in a large
(relatively young) primary prevention cohort (n¼
147,785) were not in accordance with the Dutch guide-
line. Based on multivariate regression analysis, female
sex and current smoking had the strongest association
with guideline-inconsistent treatment. When evaluating
this guideline-inconsistency, 65% of these patients had
LDL-c above the 95th percentile adjusted for age and
sex, two or more major risk factors of CVD or a




(n¼ 4667 (66)) (n¼ 2425 (34))
Age (years) 55 11 63 11 <0.001
Male sex 2056 (59) 1450 (41) <0.001
Female sex 2611 (73) 975 (27) <0.001
Systolic blood pressure (mmHg) 130 15 139 17 <0.001
Hypertension 1070 (49) 1088 (51) <0.001
Body mass index (kg/m2) 28 4.4 29 4.6 <0.001
Current smoker 764 (58) 544 (42) <0.001
Diabetes mellitus 801 (45) 988 (55) <0.001
Lipid levels (mmol/l)
Total cholesterol 6.9 1.7 7.7 1.9 <0.001
LDL-c 4.1 1.3 4.6 1.6 <0.001
HDL-c 1.5 0.4 1.3 0.4 <0.001
Triglycerides 1.4 0.8 1.9 1.3 <0.001
10-year CVD risk
Low (< 10%) 3618 (93) 293 (7) <0.001
Medium (10–19%) 874 (64) 488 (36) <0.001
High ( 20%) 175 (10) 1644 (90) <0.001
Data presented as mean SD values or n (%).
CVD: cardiovascular disease; HDL-c: high-density lipoprotein cholesterol; LDL-c: low-density lipoprotein cholesterol.
Table 3. Risk factors for guideline-inconsistent treatment based
on multivariate logistic regression analysis.
Variable OR 95% CI
Female sex 4.5 3.9–5.2
Current smoker 4.2 3.6–5.1
Positive family history of CVD 2.4 2.0–2.9
Sedentary lifestyle 1.7 1.2–2.3
Systolic blood pressure per mmHg 0.97 0.97–0.97
Body mass index per kg/m2 0.90 0.89–0.91
Age per year 0.87 0.86–0.88
LDL-c per mmol/l 0.47 0.45–0.50
Diabetes mellitus 0.09 0.08–0.11
Abbreviations: CI: confidence interval; CVD: cardiovascular disease;
LDL-c: low-density lipoprotein cholesterol; OR: odds ratio.
Table 4. Risk factor profile of patients reporting statin treat-
ment without indication.
Risk factor profile Total Male Female
(n¼ 4667) (n¼ 2056) (n¼ 2611)
All risk factors optimum 31 (1.0) 10 (.5) 21 (1.0)
1 risk factor not optimum 132 (3.0) 84 (4.0) 48 (2.0)
1 risk factor elevated 224 (5.0) 126 (6.0) 98 (4.0)
1 major risk factor 1979 (42) 946 (46) 1033 (40)
2 major risk factors 2301 (49) 890 (43) 1411 (54)
Risk factor profile based on Berry et al.11
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positive family history of premature CVD. Therefore
treatment might be reasonable in view of their lifetime
risk.
Implications for research and practice
We have shown that evidence-based guidelines do not
always translate into accurate prescribing behaviour.
Our study was not designed to explain this inconsist-
ency, but one possible explanation is that current guide-
lines do not identify young patients at increased risk of
CVD because the 10-year CVD risk calculator is pri-
marily driven by age. Many cardiovascular events
occur before the age of 60 years, i.e. before the thresh-
old levels of the risk calculators.13 This is an important
shortcoming because early identiﬁcation of patients
who will develop CVD later in life is of utmost import-
ance. It has been shown that the lifespan gain from
primary prevention interventions is greater in younger
patients.14 This is also supported by treating young
patients with familial hypercholesterolaemia.15 The
idea behind this is that lifelong exposure to elevated
risk factors accelerates the progression of atheroscler-
osis.16 Unfortunately, a randomized controlled trial in
patients with low short-term risk and increased non-
familial hypercholesterolaemia range LDL-c levels has
never been performed. The positive eﬀect of statin
treatment in medium-risk patients has previously been
shown.17 A meta-analysis of 27 statin trials shows that
statin treatment safely reduces major vascular events in
low-risk patients.18
It is possible that physicians already acknowledged
this shortcoming and used diagnostic gut feeling to pre-
scribe statins in addition to evidence-based guidelines.
Several alternative approaches to determine statin eli-
gibility have recently been suggested, including lifetime
risk,19 age- and sex-speciﬁc CVD risk thresholds,20 indi-
vidualized statin beneﬁt21 and lifespan gain from statin
treatment.14 All come with advantages and disadvan-
tages. It could also be possible to use the 95th percentile
for age and sex of LDL-c levels to identify young and
low-risk patients who could beneﬁt from statin treatment.
Apparently, based on this and other studies, phys-
icians and patients are willing to take the ‘risk’ of treat-
ing low-risk patients despite the known side-eﬀects of
statins. However, this report does not necessarily advo-
cate statin treatment in low-risk patients. Although the
latest Cholesterol Treatment Trialists meta-analysis
showed that lowering LDL-c in low-risk patients
reduces CV events,18 many questions were raised after
publication.22 Closer examination shows that statin
treatment in low-risk patients does not reduce overall
mortality and the reduction in major vascular events is
small. This reduction is driven by revascularization pro-
cedures, which is a soft cardiovascular outcome. On the
other side, some serious unwanted side-eﬀects of statins
are present.22 However, total mortality cannot be fully
captured in the Cholesterol Treatment Trialists meta-
analysis as the duration of the trials is usually only
a few years and cumulative exposure might make the
story diﬀerent in the long term. Larger eﬀect sizes of
statin treatment could be expected with increasing dur-
ation of follow-up. It may be safe to assume that
common practice is too simply end-stage CVD based
using evidence produced by short lived (5 years) LDL-c
lowering intervention studies in elderly patients.
True data on the (long-term) beneﬁts and harms of
statin treatment in low-risk patients is missing. In the
meantime, we are convinced that guidelines should
include more detailed recommendations on the treatment
of low short-term risk, but high lifetime risk patients and
simultaneously stimulate more cautious treatment.
Comparison with existing literature
Of the total 7092 patients reporting treatment,
4667 (66%) were classiﬁed as guideline-inconsistent.
This was 3.2% of the total study cohort (n¼ 147,785).
Other studies have also found a large proportion of
statin prescriptions not in accordance with guidelines.
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Figure 1. Evaluation of guideline-inconsistent treatment.
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et al.6 showed that a total of 2.7% reported inappro-
priate statin use. The percentages of guideline-inconsis-
tent treatment were comparable (69 vs. 66%). In a large
retrospective cohort analysis from >400 UK general
practices, 14% reported statin treatment and almost
60% was guideline-inconsistent.7 More recently, 6.9%
of >300,000 patients from the UK reported statin treat-
ment, of which 56% was guideline-inconsistent.8 In the
same study, 3.9% of the patients at low 10-year pre-
dicted CVD risk reported statin treatment. Another
study, using data from the Clinical Practice Research
Datalink in the UK, showed that 5.0% of participants
at low 10-year predicted CVD risk received statins.9
Of the patients at low 10-year predicted CVD risk in
our study (n¼ 135,301), 3911 (2.9%) reported statin
treatment, corresponding to 55% of the statin users.
This percentage is lower than in other studies, possibly
related to the relatively young age of our population.
Strengths and limitations
The strengths of our study are the large number of
patients included and the highly representative sample
of the population of the Netherlands.23 However,
middle-aged patients (25–49 years) are overrepresented
in Lifelines. Because most of the patients reporting
statin treatment are between 50 and 74 years (70%),
our ﬁndings could be an underestimate of the true
statin prescription at the population level. Another
advantage is the availability of the complete cardiovas-
cular risk proﬁle of the patients without statin
treatment.
Our study has several limitations. First, the lipid
values used in this analysis were corrected for statin
use. Despite the use of validated correction factors,
inconsistencies may be present on an individual level.
The correction factors were based on meta-analyses
and many randomized controlled trials, including
patients from young to old and from low to high
LDL-c levels. Percentage reductions (with 95% CIs)
were calculated. The percentage reductions were inde-
pendent of the pre-treatment conditions and therefore
suitable for our cohort. The 95% CIs of the percentage
reductions were relatively wide. For example, the 95%
CI of the percentage reduction of atorvastatin 5mg
daily was 27–36%.12 We assume that the large cohort
size will cancel out any individual inconsistencies.
Second, we assessed eligibility for statin treatment
based on the CVRM guideline. However, some phys-
icians might prefer to use internationally accepted
guidelines, although the Dutch CVRM guideline is
the most commonly used guideline in the Netherlands
and is broadly in line with international guidelines.
Therefore our ﬁndings can probably be generalized to
the related international guidelines and risk calculators
in other countries. Third, the CVRM guideline was
updated in June 2011, i.e. during the inclusion period.
Some of the participants were included in a time period
in which the previous guideline was applicable, but
most of the participants were included in 2012 and
2013.23 Only minor diﬀerences exist between the guide-
lines. Therefore we do not think that this has any mean-
ingful impact on our results. Fourth, the risk of patients
treated for hypertension is an underestimation of the
true risk. In the Dutch guideline, the estimated 10-year
CVD risk depends on systolic blood pressure, irrespect-
ive of antihypertensive medication. Using antihyperten-
sive medication is not considered to be an additional
risk factor. Therefore short-term antihypertensive
medication will underestimate the risk of CVD and
sometimes misclassify patients to a lower risk category.
However, in the analysis of guideline-inconsistent treat-
ment, the use of antihypertensive medication is con-
sidered to be a major risk factor. In patients reporting
statin treatment, some missing variables were present,
such as body mass index (n¼ 3), estimated glomerular
ﬁltration rate (n¼ 100) and daily activity (n¼ 950).
Conclusions
Taken together, our results reveal a discrepancy
between cardiovascular risk guidelines and current pre-
scribing practice for statins in primary prevention.
Two-thirds of the patients reporting statins had no indi-
cation for treatment based on the guidelines. However,
two-thirds of these guideline-inconsistent patients did
have high LDL-c levels, two or more major risk factors
for CVD or a positive family history of premature
CVD, exposing them to increased risk of future cardio-
vascular events. This discrepancy calls for better iden-
tiﬁcation of low-risk patients who could beneﬁt from
long-term statin treatment in guidelines.
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